1 option
Clinical review report : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "off" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD. Safinamide (Onstryv) (Valeo Pharma Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Systematic reviews (Medical research).
- Physical Description:
- 1 online resource
- Edition:
- Version: final (with redactions).
- Place of Publication:
- Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2020.
- Summary:
- The objective of this report was to perform a systematic review of the beneficial and harmful effects of safinamide oral tablets, 50 mg or 100 mg, as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease in patients experiencing OFF episodes while on a stable dose of levodopa.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.